Annual Report for Financial Year 2025-26

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 Date: August 24, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir / Madam, Sub.: Disclosure under Regulations 30 and 34 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and other applicable regulations - Intimation of Notice of 31st Annual General Meeting and Annual Report 2025-26 This is to inform you that the 31st Annual General Meeting of the Company will be held on Wednesday, September 16, 2026, through Video Conferencing (VC) / Other Audio - Visual Means (OAVM), at 12:00 P.M. to transact the businesses as set out in the Notice, pursuant to the relevant circulars issued in this regard by the Ministry of Corporate Affairs and under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 (Listing Regulations) as per details given below: 1. Day/Date/Time Wednesday, September 16, 2026, at 12:00 P.M. 2. Mode Through Video Conferencing (VC) / Other Audio-Visual means (OAVM) 3. Cut-off Date Wednesday, September 9, 2026 4. Remote E-Voting Sunday, September 13, 2026, from 09:00 A.M. IST and ends on Tuesday, September 15, 2026, at 05:00 P.M. IST Pursuant to Regulations 30 and 34 of the Listing Regulations, please find enclosed herewith Annual Report for the Financial Year 2025-26 and the Notice convening 31st AGM of the Company. The aforesaid documents are available on the website of the Company at www.amanta.co.in and are being dispatched electronically to shareholders whose email addresses are registered with the Company and Depositories. Further, pursuant to Regulation 36(1)(b), the Company has initiated sending physical letters providing the weblink to access the Annual Report to the shareholders whose e-mail ids are not registered with the Company/Depositories/RTA. We request you to kindly take the same on record. Thanking you, Yours faithfully, FOR, AMANTA HEALTHCARE LIMITED NIKHITA DINODIA COMPANY SECRETARY AND COMPLIANCE OFFICER Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 AMANTA HEALTHCARE LIMITED Registered & Corporate Office Manufacturing Sites Amanta Healthcare Ltd. Kheda Facility Plot no: 876, N. H. no. 8Hariyala, 8th Floor, Shaligram Corporates C. J. Marg, Ambli, Kheda – 387411, Gujarat, India Ahmedabad 380058 Gujarat, India Phone: +91 2694 287700 Phone: +91 79 6777 7600 Fax: +91 2694 287720 E-mail: info@amanta.co.in CIN: L24139GJ1994PLC023944 CCoorrppoorraattee OOvveerrvviieeww SSttaattuuttoorryy RReeppoorrttss FFiinnaanncciiaall SSttaatteemmeennttss Contents Corporate Overview GLOSSARY It’s All About Life 4 About the Company ABFS (Aseptic Blow-Fill-Seal) – A sterile manufacturing process that blows, fills, For Amanta Healthcare Limited, the belief that 5 Growth Drivers & Strategic Roadmap and seals a plastic container in one continuous, “It’s All About Life” is an acknowledgement of responsibility. enclosed operation, minimizing human contact 6 Key Financials Every product that leaves the facility is destined for a and contamination risk. hospital ward, a clinic, or a patient in need. The sterile 8 Chairman and Managing Director's Message FFS (Form Fill Seal) liquids Amanta manufactures are administered in crucial – A packaging process where a container is critical conditions, to patients who depend on their safety 10 Initial Public Offering formed from plastic film or resin, filled with and efficacy without question. product, and sealed, all on the same line. 12 Product Portfolio We take the trust that our Customers place in us very ISBM (Injection Stretch Blow Molding) seriously. This is why quality is non-negotiable. The 14 Business Model – A two-step plastic molding process where a rigorous standards Amanta upholds across formulation, preform is injection molded first, then reheated manufacturing, testing, and release exist because the end 16 Manufacturing Infrastructure and stretch-blown into its final container shape, recipient of every bottle and ampoule is a human being with often used for rigid, flexible high-clarity bottles. a life they wish to return to. 18 Geographic Presence Luer-Lock The certifications the Company holds, the regulatory 20 Environment, Social & Governance – A clouser system that enables the easy regimes it complies with, and the investments it continues withdrawal of liquids without using an additional to make in its quality infrastructure are all expressions of Community Engagement and Corporate needle. the same underlying commitment: that everything from a Social Responsibility LVP (Large Volume Parenterals) sterile injectable administered to a critically ill patient, to an ophthalmic solution applied to a patient’s eye, carries no 24 Board of Directors – Sterile injectable fluids packaged in volumes typically over 100 mL, such as IV bottle used for room for compromise. hydration or drug delivery. 26 Corporate Information This commitment extends across every geography Amanta PIC/S (Pharmaceutical Inspection Convention serves. As the Company continues to expand its export 27 Management Discussion and Analysis and Pharmaceutical Inspection Co-operation footprint across advanced and semi-regulated markets Scheme) alike, its geographic reach is as much a reflection of purpose – An international framework that harmonizes Statutory Reports as it is of commercial intent. GMP standards and inspection practices across The theme is a standard that Amanta measures itself 40 Notice member regulatory authorities. against for every batch it produces, every market it serves, Two-Port System and every decision it makes. 55 Director’s Report – An IV bottle design with two access ports (usually one for medication injection and one This is Amanta. It’s all about life. 72 Report on Corporate Governance for administration/spiking), allowing separate, controlled points of entry. Financial Statements 88 Independent Auditor’s Report 98 Balance Sheet 99 Statement of Profit and Loss 100 Statement of Cash Flows 103 Notes forming part of the Financial Statements Amanta Healthcare Limited 1 Corporate Overview Statutory Reports Financial Statements Healthcare Limited About Our Report Safe Harbour Statement Through this report, we present Amanta Healthcare Certain elements of this Report contain forward-looking Limited’s vision for driving delivery excellence, aligned with statements. These may be typically identified by terminology our core purpose, strategic priorities, and business model. used, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, It provides a transparent account of how we generate value ‘intends’, ‘estimates’, ‘plans’, ‘assumes’, and ‘anticipates’, or for our stakeholders in the short, medium, and long term, negative variations. These forward-looking statements are subject encompassing our financial outcomes, environmental to particular risks and opportunities that could be beyond the initiatives, societal contributions, and key achievements. Company’s control or currently based on the Company’s beliefs The term ‘Company’, ‘The Company’, ‘we’, ‘us’, ‘our’, and assumptions of future events. There could be a possibility of ‘Amanta’, ‘Amanta Healthcare Limited’ at all places shall the Company’s performance differing from expected outcomes and mean Amanta Healthcare Limited. performance implied in this Report. With a varied range of risks and opportunities facing the Company, no assurance can be provided BSE: 544502 | NSE: AMANTA for future results to be achieved, as the actual results may differ materially for the Co [Showing first 8,000 characters — download PDF for full document]